Absci
AI-designed protein therapeutics and antibodies
- Sector
- Biotech
- Headquarters
- VANCOUVER, WA
- Founded
- 2020
- Latest Form D
- $125M, Mar 2021
- Total capital
- $216M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $216M
- 5 Form D · last Mar 2021
- 67 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 23 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$125M
- Private capital raisedForm D · SEC · 4th filing$65M
- Private capital raisedForm D · SEC · 3rd filing$10.4M
- Private capital raisedForm D · SEC · 2nd filing$12M
- Private capital raisedForm D · SEC · 1st filing$3.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Amrit Bryan NagpalDirectorNamed in SEC Form D filings
- Andreas Bryan PihlDirectorNamed in SEC Form D filings
- Bryan LawlisDirectorNamed in SEC Form D filings
- Bryan LawlissDirectorNamed in SEC Form D filings
- Daniel GoldDirectorNamed in SEC Form D filings
- Eli Bryan CasdinDirectorNamed in SEC Form D filings
Show all 17 people
- Gregory SchiffmanExecutive OfficerNamed in SEC Form D filings
- Gustavo Bryan MahlerDirectorNamed in SEC Form D filings
- Ivana Bryan Magovcevic-LiebischDirectorNamed in SEC Form D filings
- Karen Bryan McGinnisDirectorNamed in SEC Form D filings
- Lawrence McClureExecutive OfficerNamed in SEC Form D filings
- Phil BarishExecutive Officer, DirectorNamed in SEC Form D filings
- Sean McClainExecutive Officer, DirectorNamed in SEC Form D filings
- Shelley KlassenExecutive OfficerNamed in SEC Form D filings
- V. Bryan LawlisDirectorNamed in SEC Form D filings
- Zach JonassonDirectorNamed in SEC Form D filings
- Zach Zach JonassonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 24- PendingAffinity Screening MethodUSPTOApplication 18878245
- GrantedTL1A Associated Antibody Compositions And Methods Of UseUSPTOUS 12,473,370
- PendingUnlocking De Novo Antibody Design With Generative Artificial IntelligenceUSPTOApplication 18837170
Show all 24 patent records
- Affinity Screening MethodDec 18, 2025 · Application 18878245Pending
- TL1A Associated Antibody Compositions And Methods Of UseNov 18, 2025 · US 12,473,370Granted
- Unlocking De Novo Antibody Design With Generative Artificial IntelligenceJul 3, 2025 · Application 18837170Pending
- TL1A Associated Antibody Compositions And Methods Of UseApr 3, 2025 · Application 18904989Pending
- Cancer Associated Antibody Compositions And Methods Of UseMar 20, 2025 · Application 18893664Pending
- KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSIONFeb 20, 2025 · Application 18724015Pending
- FolA Selection Assay to Identify Strains with Increased Soluble Target Protein ExpressionFeb 13, 2025 · Application 18721315Pending
- Solid-phase Screening For High-performing Bacterial StrainsFeb 13, 2025 · Application 18719906Pending
- Products And Methods For Heterologous Expression Of Proteins In A Host CellFeb 13, 2025 · Application 18723092Pending
- Expression Of Proteins Containing Non-standard Amino AcidsApplication PCTUS2025033329Pending
- TL1A Associated Antibody Compositions And Methods Of UseApplication PCTUS2024049591Pending
- Deep Learning-based Codon Optimization With Large-scale Synonymous Variant Datasets Enables Generalized Tunable Protein ExpressionApplication 19149089Pending
- Antibodies Specific To Prolactin Receptor And Therapeutic Uses ThereofApplication 63912667Pending
- High-throughput Methods For Kinetic Characterization, Quantifying And Optimizing Antibodies And Antibody Fragments Expression In BacteriaApplication PCTUS2024045761Pending
- Designing De Novo Antibody Structures By Repurposing Esmfold As A Probabilistic Denoising Diffusion ModelApplication PCTUS2024042057Pending
- TL1A Associated Antibody Compositions And Methods Of UseApplication 63682593Pending
- Antibodies Specific To Prolactin Receptor And Therapeutic Uses ThereofApplication PCTUS2025058699Pending
- TL1A Associated Antibody Compositions And Methods Of UseApplication 63675403Pending
- Expression Of Proteins Containing Non-standard Amino AcidsApplication 63659208Pending
- Antibodies Specific To Prolactin Receptor And Therapeutic Uses ThereofApplication 63744486Pending
- Solid-phase Screening For High-performing Bacterial StrainsApplication PCTUS2024032699Pending
- Half-life Extending Fc Domain Variants And Uses ThereofApplication PCTUS2024062014Pending
- Antibodies Specific To Prolactin Receptor And Therapeutic Uses ThereofApplication 63730261Pending
- ANTI-HER2 Associated Antibody Compositions Designed By Artificial Intelligence And Methods Of UseApplication PCTUS2024058893Pending
Related companies, and why
- Rivus PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Cyclerion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Endeavor BioMedicinesSimilar federal contract value in Biotech · null in contracts
- Generation BioSimilar federal contract value in Biotech · null in contracts
- Renibus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Candid TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .